Spanish neurology consensus on appropriate use of anti-amyloid antibodies in Alzheimer disease

57 Spanish neurology experts reach high consensus on anti-amyloid antibody use in Alzheimer disease—covering patient selection, ARIA monitoring, and treatment suspension—but flag equity of access and resource allocation as critical implementation hurdles.

• Consensus statement from 57 members of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group; developed January–September 2025 following European Commission approval of two anti-amyloid monoclonal antibodies.
• Prescribing centre requirements and treatment suspension criteria generated the most debate among participants; recommendations are intended to complement regulator indications, not replace them.
• Limitation: national consensus only (Spain), expert opinion–based rather than derived from new clinical trial data; document explicitly flags the need for updates as evidence and approvals evolve.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.